Assembly biosciences reports second quarter 2025 financial results and recent updates

– on track for proof-of-concept phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (hsv) helicase-primase inhibitor candidates, abi-5366 and abi-1179 –
ASMB Ratings Summary
ASMB Quant Ranking